University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Mack Roach

Mack Roach, M.D.

Radiation cancer specialist

Dr. Mack Roach III, a radiation oncologist, is an internationally renowned expert in the treatment and management of prostate cancer. His research addresses new therapies such as 3-D conformal and intensity modulated radiotherapy (IMRT) as well as brachytherapy for prostate cancer. Roach chaired one of the most important clinical trials comparing different strategies for locally advanced prostate cancer. He gained international recognition as an authority on treatment planning for prostate cancer and served as senior author for the guidelines for treatment planning published by the American College of Radiology.

Roach earned a medical degree at Stanford University School of Medicine. He is a member of several professional societies including the American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology, Radiation Therapy Oncology Group, National Cancer Institute's IMRT Working Group and American Joint Commission for Cancer Staging. He is chair of Radiation Oncology and a professor of radiation oncology, medical oncology and urology at UCSF.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level
San Francisco, CA 94143-1708
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-9807
Fax: (415) 353-9884

Hours: Monday to Friday
7 a.m. – 6 p.m.

Radiation Oncology at Parnassus
505 Parnassus Ave, Room L-75
San Francisco, CA 94143-0226
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-8335
Fax: (415) 353-7281

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Mack Roach

Education

Stanford University School of Medicine 1979

Residencies

Martin Luther King Jr General Hospital 1981
Highland General Hospital 1984
Stanford University School of Medicine 1987

Fellowships

UCSF Medical Center, Hematology/Oncology 1983

Selected Research and Publications

  1. Pan L, Baek S, Edmonds PR, Roach M, Wolkov H, Shah S, Pollack A, Hammond ME, Dicker AP. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol. 2013; 8:100.
  2. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Mar 15.
  3. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
  4. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep; 10(9):1081-7.
  5. Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83(3):e363-70.
  6. Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012 Dec; 38(8):956-67.
  7. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrence After Initial PPI for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):370-7.
  8. Meijer HJ, Debats OA, Roach M, Span PN, Witjes JA, Kaanders JH, van Lin EN, Barentsz JO. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the stephenson nomogram. Int J Radiat Oncol Biol Phys. 2012 Dec 1; 84(5):1186-91.
  9. Chang AJ, Roach M. Radium-223: down to the bone, and less is more. Oncology (Williston Park). 2012 Apr; 26(4):342, 344.
  10. Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012 Jun; 61(6):1096-106.
  11. Roach M. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012 Jul; 110(2):225.
  12. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82(5):e787-93.
  13. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb; 109 Suppl 1:22-9.
  14. Hwang AB, Chen J, Nguyen TB, Gottschalk AG, Roach MR, Pouliot J. Irradiation of the prostate and pelvic lymph nodes with an adaptive algorithm. Med Phys. 2012 Feb; 39(2):1119-24.
  15. Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M, Cheung P, Sahgal A. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):e657-62.
  16. Roach M, Thomas K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012; 2012(45):221-9.
  17. Roach M. Editorial comment. Urology. 2011 Dec; 78(6):1367-8.
  18. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75.
  19. Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R. Traditional approaches to androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S485-93.
  20. Moul JW, Kibel AS, Roach M, Dreicer R. Indications and practice with androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S478-81.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California